Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIO-RAD LABORATORIES, INC.
Report date September 10, 2020 · Filed September 14, 2020
Section 16 reporting ended · disclosed 2016-09-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 22,495 |
Ending reported balance
After 2020-09-11 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2020-09-10 · Exercise / conversion · Acquired 400 · Balance 22,030 Row 2 · 2020-09-10 · Tax withholding · Disposed 263 · Balance 21,767 Row 3 · 2020-09-10 · Exercise / conversion · Acquired 500 · Balance 22,267 Row 4 · 2020-09-10 · Tax withholding · Disposed 357 · Balance 21,910 Row 5 · 2020-09-10 · Exercise / conversion · Acquired 500 · Balance 22,410 Row 6 · 2020-09-10 · Tax withholding · Disposed 412 · Balance 21,998 Row 7 · 2020-09-10 · Exercise / conversion · Acquired 371 · Balance 22,369 Row 8 · 2020-09-10 · Tax withholding · Disposed 308 · Balance 22,061 Row 9 · 2020-09-11 · Exercise / conversion · Acquired 500 · Balance 22,561 Row 10 · 2020-09-11 · Tax withholding · Disposed 318 · Balance 22,243 Row 11 · 2020-09-11 · Exercise / conversion · Acquired 500 · Balance 22,743 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 12 · 2020-09-11 · Tax withholding · Disposed 248 · Balance 22,495 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.37 · Expires 2026-09-08 | Direct | 400 |
Reported balance
After 2020-09-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-09-10 · Exercise / conversion · Disposed 400 · Balance 400 F2: The option vests in five equal annual installments beginning on September 8, 2017. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $215.98 · Expires 2027-09-05 | Direct | 1,000 |
Reported balance
After 2020-09-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-09-10 · Exercise / conversion · Disposed 500 · Balance 1,000 F3: The option vests in five equal annual installments beginning on September 5, 2018. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $326.15 · Expires 2028-09-04 | Direct | 1,500 |
Reported balance
After 2020-09-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2020-09-10 · Exercise / conversion · Disposed 500 · Balance 1,500 F4: The option vests in five equal annual installments beginning on September 4, 2019. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $333.34 · Expires 2029-09-03 | Direct | 1,485 |
Reported balance
After 2020-09-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2020-09-10 · Exercise / conversion · Disposed 371 · Balance 1,485 F5: The option vests in five equal annual installments beginning on September 3, 2020. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.56 · Expires 2025-09-11 | Direct | 0 |
Reported balance
After 2020-09-11 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2020-09-11 · Exercise / conversion · Disposed 500 · Balance 0 F6: The option vests in five equal annual installments beginning on September 11, 2016. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-09-11 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2020-09-11 · Exercise / conversion · Disposed 500 · Balance 0 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8: The restricted stock units vest in five equal annual installments beginning on September 11, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: The option vests in five equal annual installments beginning on September 8, 2017.
F3: The option vests in five equal annual installments beginning on September 5, 2018.
F4: The option vests in five equal annual installments beginning on September 4, 2019.
F5: The option vests in five equal annual installments beginning on September 3, 2020.
F6: The option vests in five equal annual installments beginning on September 11, 2016.
F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F8: The restricted stock units vest in five equal annual installments beginning on September 11, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2017 Filed Sep 11, 2017 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000070 · edgar.xml · derivative · entry 6 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Bio-Rad A Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2017 Filed Sep 11, 2017 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 151 | $218.42 | $32,981.42 |
DisclosureSEC source: 0001652252-17-000070 · edgar.xml · nonDerivative · entry 4 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,041 Read SEC document |
| September 10, 2017 Filed Sep 11, 2017 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000070 · edgar.xml · nonDerivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000070 · edgar.xml · derivative · entry 5 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Underlying: Bio-Rad A Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 8, 2017. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 8, 2017. Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 151 | $218.42 | $32,981.42 |
DisclosureSEC source: 0001652252-17-000070 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,792 Read SEC document |
| September 08, 2017 Filed Sep 11, 2017 20:29 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000070 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 23:26 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $215.98 | $0.00 |
DisclosureSEC source: 0001652252-17-000050 · edgar.xml · derivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires 2027-09-05 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 23:26 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000050 · edgar.xml · derivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| May 18, 2017 Filed May 19, 2017 16:10 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 2,113 | $220.23 | $465,346.20 |
DisclosureSEC source: 0001315406-17-000004 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,543 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.00 to $220.75, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $75.32 | $0.00 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · derivative · entry 4 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2017-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning August 1, 2008. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 3,500 | $195.87 | $685,528.20 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · nonDerivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,656 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.11 to $196.40, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,500 | $75.32 | $263,620.00 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 20:52 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 998 | $196.16 | $195,771.37 |
DisclosureSEC source: 0001652252-17-000006 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,656 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.15 to $196.25, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 18:56 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 91 | $165.62 | $15,071.42 |
DisclosureSEC source: 0001652252-16-000134 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,654 F2 · shares: Sold by the issuer on behalf of the reporting person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 18:56 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000134 · edgar.xml · derivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning November 4, 2012. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning November 4, 2012. Read SEC document |
| November 04, 2016 Filed Nov 8, 2016 18:56 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000134 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 19:40 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 92 | $158.07 | $14,542.66 |
DisclosureSEC source: 0001652252-16-000120 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,505 F2 · shares: Sold by the issuer on behalf of the reporting person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. Read SEC document |
| September 12, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | SaleBio-Rad A Common Stock | 438 | $155.02 | $67,898.32 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · nonDerivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,357 F2 · shares: Sold by the Issuer on behalf of the Reporting Person to satisfy certain tax obligations in connection with the vesting of restricted stock units, all in accordance with a restricted stock unit award agreement. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.0162 to $155.0209, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 19:40 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000120 · edgar.xml · derivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240 Underlying: Bio-Rad A Common Stock · 240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 12, 2013. F4 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 12, 2013. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 19:40 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-16-000120 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 11, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · derivative · entry 8 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Bio-Rad A Common Stock · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F9 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F9 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · derivative · entry 7 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480 Underlying: Bio-Rad A Common Stock · 240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. F8 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2014. Read SEC document |
| September 11, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 740 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 10, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · derivative · entry 6 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Bio-Rad A Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. F7 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 10, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $160.37 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · derivative · entry 5 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Bio-Rad A Common Stock · 2,000 shares Expires 2026-09-08 F6 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 23:47 UTC | BIO-RAD LABORATORIES, INC. BIO, BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001315406-16-000040 · edgar.xml · derivative · entry 4 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Bio-Rad A Common Stock · 2,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F5 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.